Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia – An Observational Real-World Clinical Study

Figures & data

Figure 1 Example BWS scenario.

Figure 2 Example survey page asking participants to rate how important their most and least important domains are based on preceding BWS task.

Table 1 Demographic Information of Participants Using Olopatadine Hydrochloride and Mometasone Furoate Monohydrate (OLO/MOM), Participants Using Azelastine Hydrochloride and Fluticasone Propionate (AZE/FLU), and the Full Sample

Demographic Information (N = 426)	OLO/MOM n (%)	AZE/FLU n (%)	Total n (%)
Gender
Male	54 (55.1%)	77 (23.5%)	131 (30.8%)
Female	44 (44.9%)	249 (75.9%)	293 (68.8%)
Non-binary	0 (0%)	1 (0.3%)	1 (0.2%)
Prefer to self-describe	0 (0%)	0 (0%)	0 (0%)
Prefer not to answer	0 (0%)	1 (0.3%)	1 (0.2%)
Age
Less than 18 years	0 (0%)	0 (0%)	0 (0%)
18–30 years	25 (25.5%)	114 (34.8%)	139 (32.6%)
31–40 years	51 (52.0%)	93 (28.4%)	144 (33.8%)
41–50 years	12 (12.2%)	56 (17.1%)	68 (16.0%)
51–60 years	4 (4.1%)	30 (9.1%)	34 (8.0%)
61–70 years	6 (6.1%)	23 (7.0%)	29 (6.8%)
71–80 years	0 (0%)	12 (3.7%)	12 (2.8%)
81 or older	0 (0%)	0 (0%)	0 (0%)
Prefer not to answer	0 (0%)	0 (0%)	0 (0%)
State
Australian Capital Territory	5 (5.1%)	9 (2.7%)	14 (3.3%)
New South Wales	42 (42.9%)	118 (36.0%)	160 (37.6%)
Northern Territory	1 (1.0%)	0 (0%)	1 (0.2%)
Queensland	16 (16.3%)	66 (20.1%)	82 (19.2%)
South Australia	5 (5.1%)	21 (6.4%)	26 (6.1%)
Tasmania	1 (1.0%)	4 (1.2%)	5 (1.2%)
Victoria	18 (18.4%)	89 (27.1%)	107 (25.1%)
Western Australia	10 (10.2%)	21 (6.4%)	31 (7.3%)
Area
Metro/city	88 (89.8%)	253 (77.1%)	341 (80.0%)
Regional	8 (8.2%)	66 (20.1%)	74 (17.4%)
Rural	2 (2.0%)	9 (2.7%)	11 (2.6%)

Table 2 Treatment Background Information of Participants Using Olopatadine Hydrochloride and Mometasone Furoate Monohydrate (OLO/MOM), Participants Using Azelastine Hydrochloride and Fluticasone Propionate (AZE/FLU), and the Full Sample

Treatment Background (N = 426)	OLO/MOM n (%)	AZE/FLU n (%)	Total n (%)
No. of previous treatments in the last 12 months
Less than 1	50 (51.0%)	79 (24.1%)	129 (30.3%)
Equal to or more than 1	48 (49.0%)	249 (75.9%)	297 (69.7%)
Type of Allergic Rhinitis
Seasonal Allergic Rhinitis (SAR) only	36 (36.7%)	126 (38.4%)	162 (38.0%)
Perennial Allergic Rhinitis (PAR) only	23 (23.5%)	118 (36.0%)	141 (33.1%)
Both SAR and PAR	38 (38.8%)	79 (24.1%)	117 (27.5%)
Do not know/not sure	1 (1.0%)	5 (1.5%)	6 (1.4%)
Time on current treatment
Less than 1 year	58 (59.2%)	164 (50.0%)	222 (52.1%)
≥ 1 year ≤ 2 years	24 (24.5%)	103 (31.4%)	127 (29.8%)
> 2 years ≤ 3 years	6 (6.1%)	34 (10.4%)	40 (9.4%)
> 3 years ≤ 4 years	2 (2.0%)	8 (2.4%)	10 (2.3%)
> 4 years ≤ 5 years	2 (2.0%)	8 (2.4%)	10 (2.3%)
More than 5 years	5 (5.1%)	8 (2.4%)	13 (3.1%)
Do not know/not sure	1 (1.0%)	3 (0.9%)	4 (0.9%)
Who recommended current treatment
Doctor	61 (62.2%)	288 (87.8%)	349 (81.9%)
Pharmacist	29 (2.0%)	27 (8.2%)	56 (13.1%)
Self-managed	6 (29.6%)	7 (2.1%)	13 (3.1%)
Other	2 (6.1%)	6 (1.8%)	8 (1.9%)

Table 3 Descriptive Statistics of Participants Using Olopatadine Hydrochloride and Mometasone Furoate Monohydrate (OLO/MOM) and Participants Using Azelastine Hydrochloride and Fluticasone Propionate (AZE/FLU), and Between-Group Effects of One-Way MANOVA

	Rescaled Satisfaction Scores				Rescaled Importance Scores
	OLO/MOM Rescaled satisfaction scores M (SE)	AZE/FLU Rescaled satisfaction scores M (SE)	F (1424)	p	OLO/MOM Rescaled importance scores M (SE)	AZE/FLU Rescaled importance scores M (SE)	F (1424)	p
1. Immediate taste of the medication	6.12 (0.62)	4.66 (0.26)	38.30	<0.001***	5.84 (0.59)	4.63 (0.26)	24.33	<0.001***
2. Aftertaste of the medication	5.84 (0.59)	4.21 (0.23)	41.68	<0.001***	5.59 (0.56)	4.80 (0.27)	10.12	0.002**
3. Smell of the medication	6.31 (0.64)	5.55 (0.31)	17.26	<0.001***	5.20 (0.53)	3.41 (0.19)	42.95	<0.001***
4. Irritation to your nose	6.05 (0.61)	5.37 (0.30)	10.32	0.001***	6.08 (0.61)	5.51 (0.30)	8.58	0.004**
5. Urge to sneeze	6.35 (0.64)	5.52 (0.30)	17.36	<0.001***	5.88 (0.59)	4.69 (0.26)	24.35	<0.001***
6. Dripping out your nose/down your throat	6.20 (0.63)	4.89 (0.27)	29.96	<0.001***	6.29 (0.64)	5.43 (0.30)	19.88	<0.001***
7. Dryness of your nose or throat	6.41 (0.65)	5.64 (0.31)	13.92	<0.001***	6.28 (0.63)	5.49 (0.30)	17.43	<0.001***
8. Convenience (how easy it is to administer)	7.31 (0.74)	7.15 (0.39)	0.89	0.346	6.65 (0.67)	6.17 (0.34)	5.54	0.019*
9. Fast acting (how quickly it works)	7.55 (0.76)	7.16 (0.40)	3.30	0.070	7.35 (0.74)	7.48 (0.41)	0.59	0.444
10. Duration of effect (long lasting)	7.30 (0.74)	6.89 (0.38)	3.67	0.056	7.34 (0.74)	7.70 (0.43)	4.11	0.043*
11. Allergic Rhinitis symptom control (AR symptom control)	7.38 (0.75)	7.96 (0.44)	6.78	0.010**	8.00 (0.81)	8.86 (0.49)	21.64	<0.001***

Notes: N = 426 (OLO/MOM n = 98; AZE/FLU n = 328); *p ≤ 0.05; **p ≤ 0.01; ***p ≤.001.

Abbreviations: M, Mean; SE, Standard Error of the Mean.

Figure 3 Comparison of importance and satisfaction between participants using Olopatadine Hydrochloride and Mometasone Furoate Monohydrate (OLO/MOM) and participants using Azelastine Hydrochloride and Fluticasone Propionate (AZE/FLU) (OLO/MOM minus AZE/FLU scores). *, **, ***Represents a difference at p ≤ 0.05; p ≤ 0.01; p ≤.001 respectively.

Figure 4 Rescaled importance and satisfaction scores and gap between importance and satisfaction (importance minus satisfaction) for participants using Olopatadine Hydrochloride and Mometasone Furoate Monohydrate (OLO/MOM) and participants using Azelastine Hydrochloride and Fluticasone Propionate (AZE/FLU). A positive gap indicates greater importance than satisfaction, while a negative gap indicates greater satisfaction than importance.